Viz.ai adds ILD detection via IMVARIA

This partnership shows Viz.ai is moving from emergency image flagging into longitudinal disease finding, where the prize is not minutes to treatment but catching missed patients hidden in routine scans. Viz already helps hospitals route acute pulmonary embolism cases through a mobile workflow. Adding IMVARIA lets it scan large volumes of chest CTs for subtle ILD patterns, then push likely cases into specialist referral and follow up workflows inside the same hospital software footprint.1 2 3 4 5

• ILD is a very different pulmonary use case from stroke or PE. Instead of spotting an obvious emergency on a dedicated scan, the software looks across many chest CTs for faint scarring patterns that are often missed or acted on late. IMVARIA says ScreenDx runs quietly in the background and is built to drive referral to pulmonologists.2 3 4
• The deal is faster than building in house. ScreenDx received FDA 510(k) clearance in January 2025, and Viz announced the partnership on November 18, 2025. That lets Viz expand its pulmonary suite with a cleared ILD tool while keeping its core value proposition the same, detect, alert, coordinate, and move the patient to the right specialist faster.1 2 5
• This also broadens how Viz can sell into health systems. Viz says it was deployed in more than 1,800 U.S. hospitals, and its pulmonary suite now spans PE, lung nodules, COPD, and ILD related workflows. That makes the platform more useful to pulmonary service lines, not just emergency and radiology teams.1 5 6

The next step is a fuller pulmonary operating layer inside hospitals, where one vendor watches chest imaging, summarizes the patient record, surfaces guideline next steps, and routes every suspected case to the right team. If Viz keeps adding narrow, cleared algorithms through partnerships like IMVARIA, pulmonary can become a repeatable template for expansion beyond stroke into many specialty workflows.1 5 6